• +1-646-491-9876
    • +91-20-67278686

    Search

    Encephalopathy-Pipeline Review H1 2017

    Encephalopathy-Pipeline Review H1 2017

    • Report Code ID: RW0001834380
    • Category Pharmaceuticals
    • No. of Pages 48
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Encephalopathy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H1 2017, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

    Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Encephalopathy - Overview
    Encephalopathy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Encephalopathy - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Encephalopathy - Companies Involved in Therapeutics Development
    Celgene Corp
    Chiesi Farmaceutici SpA
    Fera Pharmaceuticals LLC
    GW Pharmaceuticals Plc
    JS Genetics Inc
    Knopp Biosciences LLC
    Mithra Pharmaceuticals SA
    ProThera Biologics Inc
    SciFluor Life Sciences LLC
    Takeda Pharmaceutical Company Ltd
    Encephalopathy - Drug Profiles
    Alda-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    diazoxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Estetrol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GWP-42003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    melatonin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ORP-006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    phenobarbitol sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-0034 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate Kv7.2 for Encephalopathy, Epilepsy, Neuropathic Pain and Tinnitus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Hematological Malignancies, Hypoxic-ischemic Encephalopathy and Solid Tumor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-935 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRP-601 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Encephalopathy - Dormant Projects
    Encephalopathy - Product Development Milestones
    Featured News & Press Releases
    May 12, 2017: Ovid Therapeutics to Present Preclinical Data on TAK-935/OV935 at the Antiepileptic Drug and Device Trials XIV Conference
    Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
    Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Encephalopathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Encephalopathy - Pipeline by Celgene Corp, H1 2017
    Encephalopathy - Pipeline by Chiesi Farmaceutici SpA, H1 2017
    Encephalopathy - Pipeline by Fera Pharmaceuticals LLC, H1 2017
    Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H1 2017
    Encephalopathy - Pipeline by JS Genetics Inc, H1 2017
    Encephalopathy - Pipeline by Knopp Biosciences LLC, H1 2017
    Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, H1 2017
    Encephalopathy - Pipeline by ProThera Biologics Inc, H1 2017
    Encephalopathy - Pipeline by SciFluor Life Sciences LLC, H1 2017
    Encephalopathy - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Encephalopathy - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Encephalopathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Celgene Corp
    Chiesi Farmaceutici SpA
    Fera Pharmaceuticals LLC
    GW Pharmaceuticals Plc
    JS Genetics Inc
    Knopp Biosciences LLC
    Mithra Pharmaceuticals SA
    ProThera Biologics Inc
    SciFluor Life Sciences LLC
    Takeda Pharmaceutical Company Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//encephalopathy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//encephalopathy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//encephalopathy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments